First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $11.4B — +6.1% growth in a single year.
What Could Go Wrong
1Declining reimbursement rates for elective surgeries could pressure margins, particularly in the U.S. market, where Alcon derives a significant portion of its revenue.
2Emerging competition from low-cost manufacturers in Asia is expected to erode market share in the contact lens segment, impacting revenue growth.
3Technological disruption from emerging eye care solutions, such as gene therapy for vision correction
4Regulatory changes impacting product approvals and market access
5Intensifying competition from companies like Johnson & Johnson and Bausch + Lomb in the contact lens market
6Potential market entry of new players with innovative products
7Low ROE (3.7%) raises concerns about capital efficiency and returns to shareholders
8Dependence on continuous R&D investment to maintain competitive edge